Read by QxMD icon Read


Renata de Almeida França, André de Barros Albuquerque Esteves, Cynthia de Moura Borges, Kélcia Rosana da Silva Quadros, Luiz Carlos Nogueira Falcão, Jacqueline Costa Teixeira Caramori, Rodrigo Bueno de Oliveira
Introduction: Chronic kidney disease (CKD) is associated with high morbidity and mortality rates, main causes related with cardiovascular disease (CVD) and bone mineral disorder (CKD-BMD). Uremic toxins, as advanced glycation end products (AGEs), are non-traditional cardiovascular risk factor and play a role on development of CKD-BMD in CKD. The measurement of skin autofluorescence (sAF) is a noninvasive method to assess the level of AGEs in tissue, validated in CKD patients. Objective: The aim of this study is analyze AGEs measured by sAF levels (AGEs-sAF) and its relations with CVD and BMD parameters in HD patients...
August 28, 2017: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
Lalita Prasad-Reddy, Diana Isaacs, Alexander Kantorovich
PURPOSE: Current considerations and controversies surrounding the management of chronic kidney disease (CKD) are reviewed. SUMMARY: Patients diagnosed with CKD require a unique clinical approach to prevent medication toxicities and ensure appropriate management of disease-progressing comorbidities, and they require attention to commonly occurring complications that may affect disease control and impact quality of life, including anemia and CKD-bone-mineral disorder (CKD-BMD)...
June 1, 2017: American Journal of Health-system Pharmacy: AJHP
Catharine M Sturgeon, Stuart Sprague, Alison Almond, Etienne Cavalier, William D Fraser, Alicia Algeciras-Schimnich, Ravinder Singh, Jean-Claude Souberbielle, Hubert W Vesper
Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for the exploration of calcium/phosphate disorders, and is widely used as a surrogate marker to assess skeletal and mineral disorders associated with chronic kidney disease (CKD), referred to as CKD-bone mineral disorders (CKD-MBD). CKD currently affects >10% of the adult population in the United States and represents a major health issue worldwide. Disturbances in mineral metabolism and fractures in CKD patients are associated with increased morbidity and mortality...
April 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
Sukru Ulusoy, Gulsum Ozkan, Beyhan Guvercin, Adnan Yavuz
Chronic kidney disease-mineral and bone disorder (CKD-BMD) is a condition known to be associated with cardiovascular disease and mortality in hemodialysis (HD) patients. The relation between calcium (Ca), phosphorus (P), and intact parathyroid hormone (iPTH) variability in HD patients and cardiac mortality is unknown. The purpose of this study was to assess the relation between variability in these parameters and cardiac mortality. Baseline demographic and biochemical parameters of 218 HD patients together with Ca values corrected with albumin and P values measured on a monthly basis and iPTH levels measured at 3-monthly intervals were recorded over 2 years...
November 2016: Artificial Organs
Kentaro Wada, Yuko Wada, Haruhito Adam Uchida, Shuichi Tsuruoka
BACKGROUND: Vascular calcification contributes to cardiovascular disease in hemodialysis (HD) patients with diabetes. The randomized controlled trial reported here compared the effects of lanthanum carbonate (LC) and calcium carbonate (CC) on vascular stiffness assessed using brachial-ankle pulse wave velocity (ba-PWV), intima-media thickness (IMT), bone mineral density (BMD), and serum markers of chronic kidney disease - mineral and bone disorder in such patients. METHODS: Ba-PWV, IMT, BMD, and the biomarkers osteocalcin (OC) and bone alkaline phosphatase (BAP) were examined in 43 type 2 diabetes HD patients treated with LC (n=21) or CC (n=22) for 2 years...
2015: International Journal of Nephrology and Renovascular Disease
Jeanette Bernuy, Gustavo F Gonzales
Mineral Bone Disorder (MBD) is a broad term that includes abnormal serum calcium, phosphorus, vitamin D, parathyroid hormone, growth abnormalities, bone mineralization and/or extraskeletal calcifications in patients with chronic kidney disease (CKD ). It is present in almost all patients on dialysis and may not always improve with a kidney transplant. New factors and hormones have been identified, such as Klotho and fibroblast growth factor-23 (FGF-23) that interact with vitamin D and the parathyroid hormone in the renal management of calcium and phosphorus...
April 2015: Revista Peruana de Medicina Experimental y Salud Pública
Mika Yamauchi
Lifestyle-related diseases other than type 2 diabetes mellitus and chronic kidney disease have also been reported in recent studies to have a possible effect on bone metabolism. In particular, evidence is accumulating regarding decreases in bone mineral density and an increased risk of fracture due to chronic obstructive pulmonary disease (COPD). In COPD, the fracture risk increases in both men and women, and the condition is considered a risk factor independent of glucocorticoid administration. Moreover, since kyphosis resulting from vertebral fractures adversely affects respiratory function, assessment of osteoporosis is recommended for all patients with COPD, regardless of sex...
September 2015: Clinical Calcium
Eunae Burm, Mina Ha, Ho-Jang Kwon
The association between cadmium exposure and bone mineral density (BMD) has not been well studied in young and middle-aged men. This study examined the relationship between the level of blood Cd (BCd) and BMD in a young to middle-aged representative male population while considering renal function. Using data from the 4th Korea National Health and Nutrition Examination Survey, 2008-2009, 1275 adult men aged 20-64 years were analyzed. BCd was measured by atomic absorption spectrophotometry and renal function was assessed by the estimated glomerular filtration rate (eGFR) with CKD-EPI formula...
October 2015: Journal of Trace Elements in Medicine and Biology
Jui-Hua Huang, Fu-Chou Cheng, Hsu-Chen Wu
The aim of this study is to investigate the impact of serum Mg on bone mineral metabolism in chronic kidney disease (CKD) patients with or without diabetes. A total of 56 CKD patients not receiving dialysis were recruited and divided into two groups, one group of 27 CKD patients with diabetes and another group of 29 CKD patients without diabetes. Biochemical determinations were made, and the estimated glomerular filtration rate (eGFR) was measured. Bone mineral density was measured by dual-energy X-ray absorptiometry...
2015: International Journal of Endocrinology
Xianglei Kong, Lijun Tang, Xiaojing Ma, Weiwei Liu, Zunsong Wang, Meiyu Cui, Dongmei Xu
BACKGROUND: Several studies have shown ethnic differences in bone and mineral metabolism in healthy people and patients with chronic kidney disease (CKD). However, there have been few studies regarding CKD and bone mineral density (BMD) in Chinese population. We aimed to explore the relationship between mild-to-moderate CKD and decreased BMD in Chinese adult population. METHODS: A total of 24,002 adults were enrolled in this cross-sectional study. Mild-to-moderate CKD was defined as 30 < estimated glomerular filtration rate (eGFR) < 60 mL/min/1...
September 2015: International Urology and Nephrology
Natalie Daya, Annie Voskertchian, Andrea L C Schneider, Shoshana Ballew, Mara McAdams DeMarco, Josef Coresh, Lawrence J Appel, Elizabeth Selvin, Morgan E Grams
BACKGROUND: People with end-stage renal disease are at high risk for bone fracture. Less is known about fracture risk in milder chronic kidney disease and whether chronic kidney disease-associated fracture risk varies by sex or assessment with alternative kidney markers. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 10,955 participants from the Atherosclerosis Risk in Communities (ARIC) Study followed up from 1996 to 2011...
February 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Vural Taner Yilmaz, Sebahat Ozdem, Levent Donmez, Ramazan Cetinkaya, Gultekin Suleymanlar, F Fevzi Ersoy
OBJECTIVE: The aim of the present study was to evaluate the variations of some major bone metabolism markers with reference to klotho gene polymorphism (KGP) and bone mineral density (BMD) values in patients on chronic peritoneal dialysis (CPD). MATERIALS AND METHODS: In 51 CPD patients and 40 healthy persons, assays for intact parathormone (iPTH), fibroblast growth factor 23 (FGF-23), osteoprotegerin (OPG), osteocalcin (OC), procollagen type-1 N terminal propeptide (PINP), beta- crosslaps (beta CTx), tartrate resistant acid phosphatase (TRAP5b), bone alkaline phosphatase (BAP), 1,25(OH)D3, and 25(OH)D3 and α-klotho gene mutations were performed...
June 2015: Eurasian Journal of Medicine
Junya Hirata, Kazuya Hirai, Hirobumi Asai, Chiho Matsumoto, Masaki Inada, Chisato Miyaura, Hideyuki Yamato, Mie Watanabe-Akanuma
Low-turnover bone disease is one of the bone abnormalities observed in patients with chronic kidney disease (CKD) and is recognized to be associated with low serum parathyroid hormone (PTH) level and skeletal resistance to PTH. Indoxyl sulfate (IS) is a representative uremic toxin that accumulates in the blood as renal dysfunction progresses in CKD patients. A recent in vitro study using an osteoblastic cell culture system suggests that IS has an important role in the pathogenesis of low bone turnover through induction of skeletal resistance to PTH...
October 2015: Bone
Sanket Patel, Kalpesh Gohel, Bharat Gordhanbhai Patel
Canagliflozin is a competitive, reversible, highly selective SGLT2 inhibitor and available in 100mg and 300mg as oral tablet form. Owing to this, it induced glucosuria and cause changes in glucose homeostasis without affecting insulin. This review addressed the efficacy and safety of canagliflozin in a specialized patients such as chronic kidney disease (stage III CKD), high risk cardiovascular patient and elderly population. Canagliflozin has reduced HbA1c in all the specialized population, albeit reduction is less as compared to the normal cohort...
2016: Current Diabetes Reviews
Solenne Pelletier, Guillaume Jean, Denis Fouque
Sclerostin is an osteocyte-specific glycoprotein secreted by the osteocyte and involved in the regulation of bone mass. High sclerostin levels are associated with osteoporosis, whereas low sclerostin levels are correlated with higher bone mineral density. It seems interesting to investigate a potential association between sclerostin levels and vascular calcifications since sclerostin is considered as a potent inhibitor of bone formation. In chronic kidney disease, serum sclerostin levels rise as renal function declines...
May 2015: Annales de Biologie Clinique
Aline G Costa, John P Bilezikian, E Michael Lewiecki
PURPOSE OF REVIEW: Sclerostin is a regulator of the osteoanabolic canonical Wnt signaling pathway, and thus helps to govern rates of bone formation. The Wnt pathway is also recognized as playing an important role in the pathophysiology of the chronic kidney disease-mineral and bone disorder (CKD-MBD). It also may serve as an interface between bone and the vascular system. Pharmacological inhibition of sclerostin has shown promise as an osteoanabolic approach to the treatment of osteoporosis...
July 2015: Current Opinion in Nephrology and Hypertension
Patrícia T Goldenstein, Sophie A Jamal, Rosa M A Moysés
PURPOSE OF REVIEW: Osteoporotic fractures are common and cause increased sickness and death. Men and women with chronic kidney disease (CKD) are at particularly high risk of osteoporotic fractures. Currently, however, there are no guidelines concerning noninvasive methods to assess fracture risk in CKD. Further, approved treatments to prevent fractures in otherwise healthy men and women are only recommended for use with caution in those with CKD. This review focuses on the recent data that support the use of noninvasive methods to assess fracture risk in CKD and highlights new therapies that could be used in fracture prevention in CKD...
July 2015: Current Opinion in Nephrology and Hypertension
Allison L Kuipers, Heartley Egwuogu, Rhobert W Evans, Alan L Patrick, Ada Youk, Clareann H Bunker, Joseph M Zmuda
Poor renal function is associated with increased rates of bone loss and osteoporotic fractures in Caucasian men. The importance of kidney function for skeletal health in African ancestry men, who are a population segment with a high prevalence of chronic kidney disease as well as high peak bone mass, is not well known. We examined the relationship between estimated glomerular filtration rate (eGFR) and rates of bone loss in a large population cohort of otherwise healthy Afro-Caribbean men aged 40 years and older...
December 2015: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
Patricia Palcu, Natalie Dion, Louis-Georges Ste-Marie, David Goltzman, Ina Radziunas, Paul D Miller, Sophie A Jamal
Teriparatide, a recombinant form of parathyroid hormone, is an anabolic agent approved for use in women and men with osteoporosis. However, it is not well studied in people with chronic kidney disease (CKD). We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work. Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months...
June 2015: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Hartmut H Malluche, Gustav Blomquist, Marie-Claude Monier-Faugere, Thomas L Cantor, Daniel L Davenport
Coronary artery calcifications (CACs) are observed in most patients with CKD on dialysis (CKD-5D). CACs frequently progress and are associated with increased risk for cardiovascular events, the major cause of death in these patients. A link between bone and vascular calcification has been shown. This prospective study was designed to identify noninvasive tests for predicting CAC progression, including measurements of bone mineral density (BMD) and novel bone markers in adult patients with CKD-5D. At baseline and after 1 year, patients underwent routine blood tests and measurement of CAC, BMD, and novel serum bone markers...
October 2015: Journal of the American Society of Nephrology: JASN
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"